For half a century, progress in radiation oncology has been a story about aim. First, we learned to point external beams more precisely. Then we learned to attach radioactive payloads to drug-targeting vectors that seek out cancer-associated biology, turning radiation into a systemic, targeted drug. Each step asked a version of the same question: how do we get the radiation closer to the tumor?
At Trevarx Biomedical, we think the next step asks a sharper question. Not simply how close the radiation gets to the tumor, but where it fires relative to the single most vulnerable structure inside a cancer cell: its DNA.
We call this the geometry problem. Solving it is the core idea behind AlphaPARP, our lead therapeutic.
Let us be clear about what is settled and what is not. Radiation has been used for decades to kill cancer; that is not in question. Radiopharmaceutical therapy, in which a targeting molecule carries a radioactive payload through the bloodstream, is an established and growing oncology modality. Trevarx is not inventing the idea that radiopharmaceuticals can be injected systemically for internally targeted cancer treatment. We are entering a validated field and advancing its next design question.
That question comes into focus with alpha emitters. Alpha radiation has high LET and a short range: it deposits intense, densely ionizing energy, but only over a few cell diameters. That is its power. It is also its constraint. If an alpha decay happens far from vulnerable biology, much of its advantage is lost because the energy is deposited in the wrong place.
So the frontier is no longer only which target to choose or which isotope to use. It is geometry: where the decay event occurs relative to cancer-cell DNA.
AlphaPARP is a DNA-site-targeted small-molecule alpha radiopharmaceutical. The simplest way to understand it is as three parts working as a system:
Put together, the design intent is to position a short-range, high-LET alpha event at the DNA repair site itself, rather than at the cell surface or somewhere less proximal to DNA.
Two points of discipline matter here, because they are easy to get wrong. First, the killing mechanism is radiation, not PARP inhibition. The scaffold supplies the affinity that positions the payload in the right place; it is not meant to work by shutting down the enzyme the way a conventional PARP inhibitor does. Second, our differentiation is geometry, not payload strength. We are not claiming a more powerful isotope. We are pursuing a better-placed one.
This also changes the patient-selection logic. Conventional PARP inhibitors depend on synthetic lethality: they work best when a tumor already has deficient homologous recombination repair, often described as HRD. AlphaPARP is designed differently. Its intended killing mechanism is radiation-driven, not PARP-inhibition-driven, so selection is expected to depend less on HRD status and more on whether the tumor expresses PARP1 at high levels. Ovarian cancer is our first planned clinical focus, with other PARP1-positive tumors forming the expansion path.
Geometry is a compelling idea only if location actually changes the biology. A peer-reviewed study published in the Journal of Nuclear Medicine (Lee et al., March 2026) tested the same underlying design principle: whether the subcellular location of an Astatine-211 emitter changes cytotoxicity. The study used a model system that functioned like a subcellular zip code for placing the same Astatine-211 emitter in different locations.
The finding was clear. Localizing the emitter at DNA produced the highest cytotoxicity per decay, at least 10-fold higher than cytoplasmic localization, and about twofold higher per gray after correcting for geometry. That residual per-gray advantage is consistent with the importance of alpha recoil: the short, high-energy backward kick of the daughter nucleus after alpha emission. For Astatine-211, recoil deposits roughly 131 keV over an extremely short distance.
The implication is straightforward. When the decay event occurs near DNA, the alpha track and recoil energy are positioned where they are more likely to create lethal DNA damage, including double-strand breaks.
The scientific rationale is defensible today. Clinical performance in humans remains to be proven.
Radiation works. Targeting works. Alpha radiation makes placement decisive. AlphaPARP is our answer to that placement problem: a small-molecule scaffold that carries Astatine-211 to activated PARP1 on damaged DNA, supported by a companion imaging agent, PARPTrace, to inform patient selection. Preclinical efficacy has been demonstrated in mouse models, including published neuroblastoma PDX data, with ovarian cancer studies supporting our first planned clinical focus. What we have not yet proven, and what we state plainly here, includes the human safety profile, dosimetry, dose window, repeat-dose effect, manufacturing reliability, and clinical efficacy. Those are exactly the questions our development plan is built to answer.
Geometry is the bet. The next decade of targeted alpha therapy may be won not by the strongest payload, but by the best-placed one.
Want to understand where AlphaPARP fits in the radiopharmaceutical landscape? Get in touch and we will walk you through the architecture, the evidence, and what we are working to prove next.
